# Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

> **NCT03057795** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 62 (actual)

## Conditions studied

- Classic Hodgkin Lymphoma
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03057795
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-03
- **Primary completion:** 2021-01-30
- **Final completion:** 2027-02-25
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057795, "Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03057795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*